VIC 2020 Mid-Year Update

So far, in 2020, VIC’s portfolio of companies reached numerous milestones and potential business partners are increasingly finding ways to re-engage in spite of the ongoing pandemic. The VIC Foundry has expanded...

Vixiar: Solving a Big Problem With a Small Device

Last month at Vixiar Medical, we reached a major milestone on the road to commercial launch of our Indicor™ device with the submission of our 510(k) to the FDA. We hope to have clearance to market our product in the...

Portfolio Diversification in Times of Market Volatility

Privately-Held, Science-Driven Investing in an Uncertain World As of writing this article, it’s mid-July 2020, and the uncertainty around the long-term impact of the COVID-19 pandemic continues to grow. As with any new...

The Emerging Remote Workplace: Digital Best Practices for Investor Groups

As the recent pandemic has made all too clear, organizations need to proactively prepare for the realities of a dispersed workforce, which is especially true for investor groups such as venture capital and private...

Neurexis Therapeutics Awarded Colorado Advanced Industries Accelerator Grant

AURORA, CO - Neurexis Therapeutics, Inc. announced today that it has been approved for funding as part of the Colorado Office of Economic Development and International Trade’s (OEDIT) Advanced Industries Accelerator...

Zebra Analytix Awarded NIH Funding to Improve Workplace Safety

FAYETTEVILLE, AR - Zebra Analytix—a VIC Technology Venture Development portfolio company—announced today that it has received a Small Business Innovation Research (SBIR) grant from the National Institute of...

VIC Fellow Spotlight: Dr. Natalie Gassman

The VIC Fellows Program was created in late 2019 as a mechanism for individuals with specific expertise to learn about and be involved in identifying and evaluating promising life science innovations from universities,...

Why VIC Sometimes Steps Outside Its Life Science Focus

VIC Technology Venture Development primarily is focused on building companies around high-impact life science technologies, including medical devices, therapeutics, diagnostics, and advanced instrumentation. More than...

CardioWise Makes FDA Submission With Request for Expedited Approval for COVID-19

This month, CardioWise filed a 510(k) Application for its machine learning-based heart health analysis software known as SQuEEZTM. The software, combined with cardiac computerized tomography (CT) imaging, has the...

Enjoy The Ride: Inside an Automotive Startup

Startups are known to be roller coaster rides, but what do you get when you launch an automotive industry startup? A really wild ride! The past year or so has indeed been a wild ride since I took over as CEO of...


VIC Technology Venture Development Forms New Portfolio Company: Neurexis Therapeutics
Case Study
The Emerging Remote Workplace: Digital Best Practices for Investor Groups
VIC 2019 Annual Report
White Paper
Accessing Innovation Directly from the Source - Growing Trends in Venture Capital Company Formation
VIC Portfolio Companies and Pipeline Technologies with Pandemic Impact
An Interview with Nichole Mercier at Washington University
White Paper
Sourcing Quality Innovation Beyond the VC Hot Zones
Case Study
Behind the Curtain: Opportunity Assessment at VIC Technology Venture Development
White Paper
New Paradigms of Life Science Investing
Behind the Curtain with Biolocity | Guiding Medical Innovations to Market
VIC Technology Venture Development Forms New Portfolio Company: Filtravate
White Paper
Life Science Impact Investing and the Physician Entrepreneur
From The Corner Office
SFC Fluidics Nears FDA Submission